JP2016525545A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525545A5 JP2016525545A5 JP2016529759A JP2016529759A JP2016525545A5 JP 2016525545 A5 JP2016525545 A5 JP 2016525545A5 JP 2016529759 A JP2016529759 A JP 2016529759A JP 2016529759 A JP2016529759 A JP 2016529759A JP 2016525545 A5 JP2016525545 A5 JP 2016525545A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion antibody
- acid sequence
- amino acid
- seq
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020072208A JP6914392B2 (ja) | 2013-07-22 | 2020-04-14 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361857140P | 2013-07-22 | 2013-07-22 | |
| US61/857,140 | 2013-07-22 | ||
| PCT/US2014/038660 WO2015012944A1 (en) | 2013-07-22 | 2014-05-19 | Methods and compositions for increasing enzyme activity in the cns |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020072208A Division JP6914392B2 (ja) | 2013-07-22 | 2020-04-14 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016525545A JP2016525545A (ja) | 2016-08-25 |
| JP2016525545A5 true JP2016525545A5 (enExample) | 2017-06-29 |
| JP6692293B2 JP6692293B2 (ja) | 2020-05-13 |
Family
ID=51023055
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016529759A Active JP6692293B2 (ja) | 2013-07-22 | 2014-05-19 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
| JP2020072208A Active JP6914392B2 (ja) | 2013-07-22 | 2020-04-14 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
| JP2021115534A Pending JP2021180658A (ja) | 2013-07-22 | 2021-07-13 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
| JP2023153971A Pending JP2024012225A (ja) | 2013-07-22 | 2023-09-20 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
| JP2024230169A Pending JP2025041923A (ja) | 2013-07-22 | 2024-12-26 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020072208A Active JP6914392B2 (ja) | 2013-07-22 | 2020-04-14 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
| JP2021115534A Pending JP2021180658A (ja) | 2013-07-22 | 2021-07-13 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
| JP2023153971A Pending JP2024012225A (ja) | 2013-07-22 | 2023-09-20 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
| JP2024230169A Pending JP2025041923A (ja) | 2013-07-22 | 2024-12-26 | Ｃｎｓにおける酵素活性を増大するための方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20150023956A1 (enExample) |
| EP (2) | EP3024848B1 (enExample) |
| JP (5) | JP6692293B2 (enExample) |
| AU (2) | AU2014293626A1 (enExample) |
| CA (1) | CA2918579C (enExample) |
| WO (1) | WO2015012944A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5959795B2 (ja) | 2006-08-18 | 2016-08-02 | アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． | 血液脳関門送達のための物質 |
| EP2997976A1 (en) | 2007-07-27 | 2016-03-23 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
| US9533055B2 (en) | 2009-03-18 | 2017-01-03 | Armagen Technologies, Inc. | Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins |
| SI2485761T1 (sl) | 2009-10-09 | 2019-05-31 | Armagen, Inc. | Postopki in sestavki za povečanje aktivnosti iduronat-2-sulfataze v CŽS |
| US8486399B2 (en) * | 2011-12-02 | 2013-07-16 | Armagen Technologies, Inc. | Methods and compositions for increasing arylsulfatase A activity in the CNS |
| US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| CN109071634A (zh) | 2016-04-26 | 2018-12-21 | R.P.谢勒技术有限责任公司 | 抗体偶联物及其制备和使用方法 |
| MX2020002918A (es) | 2017-10-02 | 2020-07-22 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas. |
| CA3107749A1 (en) * | 2018-08-07 | 2020-02-13 | Armagen, Inc. | Methods and compositions for increasing the activity in the cns of hexosaminidase a, acid sphingomyelinase, and palmitoyl-protein thioesterase 1 |
| AU2021362209B2 (en) | 2020-10-14 | 2026-02-12 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
| US20250289861A1 (en) * | 2022-05-04 | 2025-09-18 | Immunoforge Co.,Ltd. | Fusion protein comprising glp-1, immunoglobulin fc, and igf-1 and use thereof |
| WO2023240220A1 (en) * | 2022-06-09 | 2023-12-14 | The University Of North Carolina At Chapel Hill | Aav-sgsh vectors for treatment of mucopolysaccharidosis iiia |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5182107A (en) * | 1989-09-07 | 1993-01-26 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
| TW279133B (enExample) | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| US6060069A (en) | 1991-05-20 | 2000-05-09 | Dura Pharmaceuticals, Inc. | Pulmonary delivery of pharmaceuticals |
| US6195608B1 (en) | 1993-05-28 | 2001-02-27 | Lucent Technologies Inc. | Acoustic highway monitor |
| US5997501A (en) | 1993-11-18 | 1999-12-07 | Elan Corporation, Plc | Intradermal drug delivery device |
| US5656284A (en) | 1995-04-24 | 1997-08-12 | Balkin; Michael S. | Oral transmucosal delivery tablet and method of making it |
| KR100523754B1 (ko) | 1995-09-19 | 2007-06-04 | 아스텔라스세이야쿠 가부시키가이샤 | 에어졸조성물 |
| WO1998054213A2 (en) * | 1997-05-30 | 1998-12-03 | Amgen Inc. | Neurotrophic factor receptors |
| US6016800A (en) | 1997-10-24 | 2000-01-25 | Century; Theodore J. | Intrapulmonary aerosolizer |
| CN1206004C (zh) | 1997-12-11 | 2005-06-15 | 阿尔扎有限公司 | 增强透皮物剂流量的装置 |
| US6348210B1 (en) | 1998-11-13 | 2002-02-19 | Alza Corporation | Methods for transdermal drug administration |
| US6375975B1 (en) | 1998-12-21 | 2002-04-23 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary application |
| US6284262B1 (en) | 1999-01-26 | 2001-09-04 | Virgil A. Place | Compact dosage unit for buccal administration of a pharmacologically active agent |
| US7388079B2 (en) | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| US20050142141A1 (en) * | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
| CN101444621B (zh) * | 2003-02-11 | 2013-11-20 | 夏尔人类遗传性治疗公司 | 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗 |
| WO2004108071A2 (en) * | 2003-06-05 | 2004-12-16 | Salk Institute For Biological Studies | Targeting polypeptides to the central nervous system |
| SI2485761T1 (sl) * | 2009-10-09 | 2019-05-31 | Armagen, Inc. | Postopki in sestavki za povečanje aktivnosti iduronat-2-sulfataze v CŽS |
| CA2805413A1 (en) * | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | Methods and compositions for cns delivery of heparan n-sulfatase |
| WO2012075037A1 (en) * | 2010-11-30 | 2012-06-07 | Genentech, Inc. | Low affinity blood brain barrier receptor antibodies and uses therefor |
| AU2010366066B2 (en) * | 2010-12-22 | 2016-01-14 | Fondazione Telethon | Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses |
| US8486399B2 (en) * | 2011-12-02 | 2013-07-16 | Armagen Technologies, Inc. | Methods and compositions for increasing arylsulfatase A activity in the CNS |
| US20130323221A1 (en) * | 2012-05-30 | 2013-12-05 | Biostrategies LC | Plant lectins as carriers of associated drug substances into animal and human cells |
-
2014
- 2014-05-19 CA CA2918579A patent/CA2918579C/en active Active
- 2014-05-19 AU AU2014293626A patent/AU2014293626A1/en not_active Abandoned
- 2014-05-19 JP JP2016529759A patent/JP6692293B2/ja active Active
- 2014-05-19 EP EP14733790.1A patent/EP3024848B1/en active Active
- 2014-05-19 US US14/281,803 patent/US20150023956A1/en not_active Abandoned
- 2014-05-19 WO PCT/US2014/038660 patent/WO2015012944A1/en not_active Ceased
- 2014-05-19 EP EP20179064.9A patent/EP3730516A1/en active Pending
-
2020
- 2020-01-14 AU AU2020200250A patent/AU2020200250A1/en not_active Abandoned
- 2020-04-14 JP JP2020072208A patent/JP6914392B2/ja active Active
- 2020-06-18 US US16/905,292 patent/US20200308292A1/en not_active Abandoned
-
2021
- 2021-07-13 JP JP2021115534A patent/JP2021180658A/ja active Pending
-
2022
- 2022-06-22 US US17/846,999 patent/US20220348672A1/en not_active Abandoned
-
2023
- 2023-09-20 JP JP2023153971A patent/JP2024012225A/ja active Pending
-
2024
- 2024-12-26 JP JP2024230169A patent/JP2025041923A/ja active Pending